GLP-1 drug shortages, driven by cosmetic and weight loss purposes, result in access disparities among individuals with ...
As the FDA issues a new warning about aspiration across all GLP-1 weight loss drugs, doctor groups are giving new ...
GLP-1 agonist drugs like Ozempic, and SLGT2 inhibitor drugs like Jardiance have been linked with a lower risk of a second ...
Poorer folks' access to blockbuster weight-loss drugs through Medicaid ... treatment of obesity using glucagon-like peptide-1 agonist (GLP-1) medications, researchers discovered.
The FDA is warning that patients taking GLP-1s may be at a higher risk of inhaling fluid into their lungs while under ...
SAN ANTONIO -- Research presented at the ObesityWeek annual meeting included studies on rationing of prescription medications ...
In addition to ensuring equitable access to the glucagon-like peptide-1 (GLP-1 ... interest in these ...